Kimberley Jackson
Eli Lilly (United States)(US)Eli Lilly (United Kingdom)(GB)
Publications by Year
Research Areas
Neuroscience and Neuropharmacology Research, Psoriasis: Treatment and Pathogenesis, Receptor Mechanisms and Signaling, Pharmaceutical studies and practices, Pharmacogenetics and Drug Metabolism
Most-Cited Works
- → Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial(2007)1,032 cited
- → Neutrophil elastase inhibition in acute lung injury: Results of the STRIVE study(2004)344 cited
- → A Multicenter, Inpatient, Phase 2, Double-Blind, Placebo-Controlled Dose-Ranging Study of LY2140023 Monohydrate in Patients With DSM-IV Schizophrenia(2011)255 cited
- → Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications(2012)204 cited
- → N-(4-((2-(trifluoromethyl)-3-hydroxy-4-(isobutyryl)phenoxy)methyl)benzyl)-1-methyl-1H-imidazole-4-carboxamide (THIIC), a Novel Metabotropic Glutamate 2 Potentiator with Potential Anxiolytic/Antidepressant Properties: In Vivo Profiling Suggests a Link between Behavioral and Central Nervous System Neurochemical Changes(2010)99 cited
- → Drug–excipient interactions and their affect on absorption(2000)99 cited